Plasma Proteomic Signatures in Early Chronic Obstructive Pulmonary Disease

Purpose Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2‐DE followed by MALDI TOF‐MS analyses in order to identify potential bioma...

Full description

Saved in:
Bibliographic Details
Published inProteomics. Clinical applications Vol. 12; no. 3; pp. e1700088 - n/a
Main Authors Baralla, Angela, Fois, Alessandro G., Sotgiu, Elisabetta, Zinellu, Elisabetta, Mangoni, Arduino A., Sotgia, Salvatore, Zinellu, Angelo, Pirina, Pietro, Carru, Ciriaco
Format Journal Article
LanguageEnglish
Published Germany Wiley Subscription Services, Inc 01.05.2018
Subjects
Online AccessGet full text
ISSN1862-8346
1862-8354
1862-8354
DOI10.1002/prca.201700088

Cover

Loading…
Abstract Purpose Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2‐DE followed by MALDI TOF‐MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate. Experimental design Blood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age‐ and sex‐matched control subjects. Proteome analysis was based on 2D‐Page followed by MALDI‐TOF MS identifications. Validation was made on two significant proteins by western blotting. Results The analyses revealed 29 between‐group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha‐1 chain C), blood coagulation and complement pathways (prothrombin, complement 4‐B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A‐I, and apolipoprotein E). Conclusion and clinical relevance These results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.
AbstractList Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2-DE followed by MALDI TOF-MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate. Blood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age- and sex-matched control subjects. Proteome analysis was based on 2D-Page followed by MALDI-TOF MS identifications. Validation was made on two significant proteins by western blotting. The analyses revealed 29 between-group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha-1 chain C), blood coagulation and complement pathways (prothrombin, complement 4-B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A-I, and apolipoprotein E). These results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2-DE followed by MALDI TOF-MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate.PURPOSEChronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2-DE followed by MALDI TOF-MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate.Blood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age- and sex-matched control subjects. Proteome analysis was based on 2D-Page followed by MALDI-TOF MS identifications. Validation was made on two significant proteins by western blotting.EXPERIMENTAL DESIGNBlood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age- and sex-matched control subjects. Proteome analysis was based on 2D-Page followed by MALDI-TOF MS identifications. Validation was made on two significant proteins by western blotting.The analyses revealed 29 between-group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha-1 chain C), blood coagulation and complement pathways (prothrombin, complement 4-B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A-I, and apolipoprotein E).RESULTSThe analyses revealed 29 between-group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha-1 chain C), blood coagulation and complement pathways (prothrombin, complement 4-B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A-I, and apolipoprotein E).These results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.CONCLUSION AND CLINICAL RELEVANCEThese results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.
Purpose Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2‐DE followed by MALDI TOF‐MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate. Experimental design Blood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age‐ and sex‐matched control subjects. Proteome analysis was based on 2D‐Page followed by MALDI‐TOF MS identifications. Validation was made on two significant proteins by western blotting. Results The analyses revealed 29 between‐group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha‐1 chain C), blood coagulation and complement pathways (prothrombin, complement 4‐B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A‐I, and apolipoprotein E). Conclusion and clinical relevance These results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.
PurposeChronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled noxious particles or gases. We used a proteomic approach with 2‐DE followed by MALDI TOF‐MS analyses in order to identify potential biomarkers in the early stages of the disease: global initiative for chronic obstructive pulmonary disease (GOLD) stage mild and moderate.Experimental designBlood plasma was collected from 43 patients with mild and moderate COPD as well as from 43 age‐ and sex‐matched control subjects. Proteome analysis was based on 2D‐Page followed by MALDI‐TOF MS identifications. Validation was made on two significant proteins by western blotting.ResultsThe analyses revealed 29 between‐group differences in expressed spots, belonging to 20 unique proteins. These proteins are involved in inflammation (haptoglobin, Ig alpha‐1 chain C), blood coagulation and complement pathways (prothrombin, complement 4‐B, ApoH), oxidative stress (ceruloplasmin, vitamin D binding protein, and serotransferrin), and lipoprotein/lipid metabolism (apolipoprotein A‐I, and apolipoprotein E).Conclusion and clinical relevanceThese results indicate that specific proteomic signatures can be detected and useful in terms of treatment selection and in early COPD patient monitoring.
Author Zinellu, Angelo
Fois, Alessandro G.
Sotgiu, Elisabetta
Zinellu, Elisabetta
Pirina, Pietro
Carru, Ciriaco
Baralla, Angela
Sotgia, Salvatore
Mangoni, Arduino A.
Author_xml – sequence: 1
  givenname: Angela
  surname: Baralla
  fullname: Baralla, Angela
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 2
  givenname: Alessandro G.
  surname: Fois
  fullname: Fois, Alessandro G.
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 3
  givenname: Elisabetta
  surname: Sotgiu
  fullname: Sotgiu, Elisabetta
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 4
  givenname: Elisabetta
  surname: Zinellu
  fullname: Zinellu, Elisabetta
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 5
  givenname: Arduino A.
  surname: Mangoni
  fullname: Mangoni, Arduino A.
  organization: Flinders University
– sequence: 6
  givenname: Salvatore
  surname: Sotgia
  fullname: Sotgia, Salvatore
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 7
  givenname: Angelo
  surname: Zinellu
  fullname: Zinellu, Angelo
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 8
  givenname: Pietro
  surname: Pirina
  fullname: Pirina, Pietro
  organization: Azienda Ospedaliero Universitaria di Sassari
– sequence: 9
  givenname: Ciriaco
  surname: Carru
  fullname: Carru, Ciriaco
  email: carru@uniss.it
  organization: Azienda Ospedaliero Universitaria di Sassari
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29412517$$D View this record in MEDLINE/PubMed
BookMark eNqFkbtPwzAQxi0EAgqsjCgSC0uKz3YSe0SlvITUiMdsOcYBo8QudgLqf08qSocune6k-333-kZo13lnEDoFPAaMyeU8aDUmGAqMMec76BB4TlJOM7a7zll-gEYxfmKcMVLgfXRABAOSQXGIHspGxVYlZfCd8a3VybN9d6rrg4mJdclUhWaRTD6Cd0NtVsUu9Lqz3yYp-6b1ToVFcm2jUdEco71aNdGcrOIRer2Zvkzu0sfZ7f3k6jHVNOcsFVxUghd1UWcEtFYY0woKWlBOGKu1zkhtiKqoyXKdKcXpmxEAnAIbspoDPUIXf33nwX_1JnaytVGbplHO-D5KEEKAIATyAT3fQD99H9ywnSSY0gIYJ0vqbEX1VWve5DzYdrhL_n9pAMZ_gA4-xmDqNQJYLm2QSxvk2oZBwDYE2naqs951Qdlmq-zHNmaxZYgsnyZXICijvwfEmh4
CitedBy_id crossref_primary_10_1002_jimd_12344
crossref_primary_10_1016_j_lfs_2019_05_047
crossref_primary_10_1002_elps_201800305
crossref_primary_10_1080_17476348_2024_2375418
crossref_primary_10_2147_COPD_S408361
crossref_primary_10_3390_jcm9113426
crossref_primary_10_1016_j_rmed_2020_106282
crossref_primary_10_3390_proteomes10030025
crossref_primary_10_1002_iid3_1090
crossref_primary_10_1038_s41598_023_32216_0
crossref_primary_10_1007_s11916_024_01244_4
crossref_primary_10_1186_s12950_022_00308_9
crossref_primary_10_1016_j_jprot_2018_07_009
crossref_primary_10_1088_1752_7163_ac15ea
Cites_doi 10.1182/blood-2010-12-325951
10.1186/1465-9921-8-85
10.1021/pr800423x
10.1182/blood-2011-02-339564
10.1378/chest.08-1583
10.1016/S0140-6736(12)61728-0
10.1189/jlb.0208100
10.1183/09031936.00004110
10.1111/j.1398-9995.2008.01817.x
10.1164/rccm.200709-1412OC
10.1164/ajrccm.163.5.2101039
10.1164/rccm.200703-456SO
10.1021/bi034057k
10.1164/ajrccm.157.3.9709027
10.1002/pmic.200401015
10.1016/B978-0-12-386960-9.00017-4
10.1186/s12931-016-0471-z
10.1378/chest.109.1.115
10.1007/978-1-61779-885-6_3
10.1136/thx.2009.128793
10.1016/j.rmed.2008.07.007
10.1378/chest.112.2.341
10.1378/chest.128.3.1239
10.1016/j.amjmed.2005.06.041
10.1136/thx.2010.140921
10.1164/rccm.200906-0857OC
10.1136/thx.2008.102079
10.1016/j.pupt.2010.10.010
10.1046/j.1538-7836.2003.00063.x
10.1586/epr.09.80
10.1021/pr070440q
10.1164/ajrccm.155.3.9117016
10.1002/pmic.200401180
10.1111/j.1365-2796.2003.01211.x
10.1164/ajrccm.152.5.7582312
10.1371/journal.pone.0096285
10.1056/NEJM200007273430407
10.1016/S0140-6736(06)68516-4
10.1164/rccm.201010-1623OC
10.1385/CBB:43:1:167
10.1371/journal.pone.0129291
10.1016/j.thromres.2011.05.004
10.1586/epr.10.9
10.1378/chest.117.2_suppl.10S
10.1164/rccm.200703-409OC
10.1093/nar/gku1003
10.1111/eci.12582
10.4049/jimmunol.144.6.2371
ContentType Journal Article
Copyright 2018 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Copyright_xml – notice: 2018 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
– notice: 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7TM
7TO
8FD
FR3
H94
K9.
P64
RC3
7X8
DOI 10.1002/prca.201700088
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1862-8354
EndPage n/a
ExternalDocumentID 29412517
10_1002_prca_201700088
PRCA1934
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Ministero dell'Università e della Ricerca
– fundername: Fondazione Banco di Sardegna
GroupedDBID ---
05W
0R~
123
1OC
33P
3SF
3WU
4.4
52U
52V
53G
8-1
8UM
A00
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCUV
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZFZN
AZVAB
BDRZF
BHBCM
BNHUX
BOGZA
BRXPI
CS3
DCZOG
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F5P
FEDTE
G-S
GODZA
HF~
HGLYW
HVGLF
HZ~
IX1
KBYEO
LATKE
LAW
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
NNB
O66
O9-
P2W
P4E
PQQKQ
RNS
ROL
SUPJJ
SV3
W99
WBKPD
WIH
WIJ
WIK
WNSPC
WOHZO
WXSBR
WYISQ
WYJ
XV2
~S-
AAYXX
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7TM
7TO
8FD
FR3
H94
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3684-989b987f7f521cca003b173738244fcc52fe2ab3e56c5aa83de91183143def813
IEDL.DBID DR2
ISSN 1862-8346
1862-8354
IngestDate Fri Jul 11 03:17:24 EDT 2025
Fri Jul 25 09:25:29 EDT 2025
Mon Jul 21 05:39:18 EDT 2025
Tue Jul 01 02:14:14 EDT 2025
Thu Apr 24 23:03:54 EDT 2025
Wed Jan 22 16:30:59 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords 2D-page
inflammation
oxidative stress
COPD
Language English
License 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3684-989b987f7f521cca003b173738244fcc52fe2ab3e56c5aa83de91183143def813
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 29412517
PQID 2033714826
PQPubID 1016438
PageCount 12
ParticipantIDs proquest_miscellaneous_1999192216
proquest_journals_2033714826
pubmed_primary_29412517
crossref_primary_10_1002_prca_201700088
crossref_citationtrail_10_1002_prca_201700088
wiley_primary_10_1002_prca_201700088_PRCA1934
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2018
2018-05-00
20180501
PublicationDateYYYYMMDD 2018-05-01
PublicationDate_xml – month: 05
  year: 2018
  text: May 2018
PublicationDecade 2010
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
PublicationTitle Proteomics. Clinical applications
PublicationTitleAlternate Proteomics Clin Appl
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 1996; 109
2011; 118
2011; 117
1997; 155
1997; 112
2008; 7
2010; 181
2008; 102
1998; 157
1990; 144
2010; 65
2012; 893
2011; 128
2007; 176
2006; 27
2015; 43
2007; 8
2007; 6
2011; 66
2011; 24
2003; 1
2014; 9
2010; 7
2003; 42
1990; 92
2016; 46
2006; 367
2010; 36
2001; 163
2009; 64
2010
2000; 117
2012; 380
2015; 10
2005; 118
2008; 12
2009; 135
2006
2005; 43
2016; 17
1995; 152
2003; 254
2005; 128
2011; 86
2005; 5
2016; 20
2016
2009; 6
2000; 343
2008; 178
2008; 84
2011; 183
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_47_1
e_1_2_8_26_1
e_1_2_8_49_1
e_1_2_8_3_1
Paone G. (e_1_2_8_12_1) 2016; 20
e_1_2_8_5_1
e_1_2_8_7_1
Verrills N. M. (e_1_2_8_13_1) 2006; 27
e_1_2_8_9_1
e_1_2_8_20_1
e_1_2_8_22_1
e_1_2_8_45_1
Milevoj Kopcinovic L. (e_1_2_8_55_1) 2016
e_1_2_8_1_1
e_1_2_8_41_1
e_1_2_8_17_1
e_1_2_8_19_1
Robbins R. A. (e_1_2_8_50_1) 1990; 144
e_1_2_8_36_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_32_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_53_1
e_1_2_8_51_1
e_1_2_8_30_1
e_1_2_8_29_1
Mak J. C. (e_1_2_8_43_1) 2008; 12
e_1_2_8_25_1
e_1_2_8_46_1
e_1_2_8_27_1
e_1_2_8_48_1
e_1_2_8_2_1
e_1_2_8_4_1
e_1_2_8_6_1
e_1_2_8_8_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_23_1
e_1_2_8_44_1
e_1_2_8_40_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_16_1
e_1_2_8_37_1
Chauhan S. (e_1_2_8_33_1) 1990; 92
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_54_1
e_1_2_8_52_1
References_xml – volume: 176
  start-page: 532
  year: 2007
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 84
  start-page: 170
  year: 2008
  publication-title: J. Leukocyte Biol.
– start-page: 1
  year: 2016
  publication-title: Biomark.: Biochem. Indic. Expo., Response, Susceptibility Chem.
– volume: 42
  start-page: 9365
  year: 2003
  publication-title: Biochemistry
– volume: 128
  start-page: 1239
  year: 2005
  publication-title: Chest
– volume: 157
  start-page: 822
  year: 1998
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 178
  start-page: 444
  year: 2008
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 12
  start-page: 368
  year: 2008
  publication-title: Int. J. Tuberc. Lung Disease: Off. J. Int. Union Against Tuberc. Lung Disease
– volume: 5
  start-page: 2972
  year: 2005
  publication-title: Proteomics
– volume: 8
  start-page: 85
  year: 2007
  publication-title: Respir. Res.
– volume: 367
  start-page: 1216
  year: 2006
  publication-title: Lancet
– volume: 254
  start-page: 540
  year: 2003
  publication-title: J. Intern. Med.
– volume: 66
  start-page: 205
  year: 2011
  publication-title: Thorax
– volume: 155
  start-page: 852
  year: 1997
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 65
  start-page: 456
  year: 2010
  publication-title: Thorax
– volume: 7
  start-page: 5125
  year: 2008
  publication-title: J. Proteome Res.
– volume: 10
  start-page: e0129291
  year: 2015
  publication-title: PLoS One
– volume: 6
  start-page: 4615
  year: 2007
  publication-title: J. Proteome Res.
– volume: 92
  start-page: 241
  year: 1990
  publication-title: Indian J. Med. Res.
– volume: 380
  start-page: 2095
  year: 2012
  publication-title: Lancet
– volume: 24
  start-page: 32
  year: 2011
  publication-title: Pulm. Pharmacol. Ther.
– volume: 112
  start-page: 341
  year: 1997
  publication-title: Chest
– volume: 117
  start-page: 6939
  year: 2011
  publication-title: Blood
– volume: 46
  start-page: 181
  year: 2016
  publication-title: Eur. J. Clin. Invest.
– volume: 102
  start-page: 1833
  year: 2008
  publication-title: Respir. Med.
– volume: 118
  start-page: 1364
  year: 2005
  publication-title: Am. J. Med.
– volume: 20
  start-page: 698
  year: 2016
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 109
  start-page: 115
  year: 1996
  publication-title: Chest
– volume: 27
  start-page: 99
  year: 2006
  publication-title: Clin. Biochem. Rev./Aus. Assoc. Clin. Biochemists
– volume: 7
  start-page: 361
  year: 2010
  publication-title: Expert Rev. Proteomics
– volume: 5
  start-page: 654
  year: 2005
  publication-title: Proteomics
– volume: 9
  start-page: e96285
  year: 2014
  publication-title: PLoS One
– volume: 43
  start-page: 167
  year: 2005
  publication-title: Cell Biochem. Biophys.
– volume: 152
  start-page: 1666
  year: 1995
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 86
  start-page: 379
  year: 2011
  publication-title: Vitam. Horm.
– volume: 43
  start-page: D447
  year: 2015
  publication-title: Nucleic Acids Res.
– year: 2010
– volume: 135
  start-page: 344
  year: 2009
  publication-title: Chest
– volume: 893
  start-page: 37
  year: 2012
  publication-title: Methods Mol. Biol.
– volume: 117
  start-page: 10S
  year: 2000
  publication-title: Chest
– volume: 64
  start-page: 47
  year: 2009
  publication-title: Allergy
– volume: 163
  start-page: 1256
  year: 2001
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 118
  start-page: 2774
  year: 2011
  publication-title: Blood
– volume: 181
  start-page: 1049
  year: 2010
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 128
  start-page: e24
  year: 2011
  publication-title: Thromb. Res.
– volume: 178
  start-page: 1211
  year: 2008
  publication-title: Am. J. Respir. Crit. Care Med.
– year: 2006
– volume: 183
  start-page: 1633
  year: 2011
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 343
  start-page: 269
  year: 2000
  publication-title: N. Engl. J. Med.
– volume: 144
  start-page: 2371
  year: 1990
  publication-title: J. Immunol.
– volume: 64
  start-page: 211
  year: 2009
  publication-title: Thorax
– volume: 36
  start-page: 1259
  year: 2010
  publication-title: Eur. Respir. J.
– volume: 1
  start-page: 231
  year: 2003
  publication-title: J. Thromb. Haemost.: JTH
– volume: 6
  start-page: 619
  year: 2009
  publication-title: Expert Rev. Proteomics
– volume: 17
  start-page: 150
  year: 2016
  publication-title: Respir. Res.
– ident: e_1_2_8_35_1
  doi: 10.1182/blood-2010-12-325951
– ident: e_1_2_8_31_1
  doi: 10.1186/1465-9921-8-85
– volume: 92
  start-page: 241
  year: 1990
  ident: e_1_2_8_33_1
  publication-title: Indian J. Med. Res.
– ident: e_1_2_8_16_1
  doi: 10.1021/pr800423x
– ident: e_1_2_8_34_1
  doi: 10.1182/blood-2011-02-339564
– ident: e_1_2_8_36_1
– ident: e_1_2_8_17_1
  doi: 10.1378/chest.08-1583
– ident: e_1_2_8_2_1
  doi: 10.1016/S0140-6736(12)61728-0
– ident: e_1_2_8_48_1
  doi: 10.1189/jlb.0208100
– ident: e_1_2_8_29_1
  doi: 10.1183/09031936.00004110
– ident: e_1_2_8_42_1
  doi: 10.1111/j.1398-9995.2008.01817.x
– ident: e_1_2_8_38_1
  doi: 10.1164/rccm.200709-1412OC
– ident: e_1_2_8_22_1
  doi: 10.1164/ajrccm.163.5.2101039
– ident: e_1_2_8_10_1
  doi: 10.1164/rccm.200703-456SO
– ident: e_1_2_8_41_1
  doi: 10.1021/bi034057k
– ident: e_1_2_8_6_1
  doi: 10.1164/ajrccm.157.3.9709027
– ident: e_1_2_8_24_1
  doi: 10.1002/pmic.200401015
– ident: e_1_2_8_1_1
  doi: 10.1016/B978-0-12-386960-9.00017-4
– ident: e_1_2_8_45_1
  doi: 10.1186/s12931-016-0471-z
– ident: e_1_2_8_4_1
  doi: 10.1378/chest.109.1.115
– ident: e_1_2_8_23_1
  doi: 10.1007/978-1-61779-885-6_3
– start-page: 1
  year: 2016
  ident: e_1_2_8_55_1
  publication-title: Biomark.: Biochem. Indic. Expo., Response, Susceptibility Chem.
– volume: 12
  start-page: 368
  year: 2008
  ident: e_1_2_8_43_1
  publication-title: Int. J. Tuberc. Lung Disease: Off. J. Int. Union Against Tuberc. Lung Disease
– ident: e_1_2_8_51_1
  doi: 10.1136/thx.2009.128793
– ident: e_1_2_8_9_1
– ident: e_1_2_8_28_1
  doi: 10.1016/j.rmed.2008.07.007
– ident: e_1_2_8_32_1
  doi: 10.1378/chest.112.2.341
– ident: e_1_2_8_27_1
  doi: 10.1378/chest.128.3.1239
– ident: e_1_2_8_26_1
  doi: 10.1016/j.amjmed.2005.06.041
– ident: e_1_2_8_49_1
  doi: 10.1136/thx.2010.140921
– ident: e_1_2_8_21_1
  doi: 10.1164/rccm.200906-0857OC
– ident: e_1_2_8_53_1
  doi: 10.1136/thx.2008.102079
– ident: e_1_2_8_30_1
  doi: 10.1016/j.pupt.2010.10.010
– ident: e_1_2_8_40_1
  doi: 10.1046/j.1538-7836.2003.00063.x
– ident: e_1_2_8_14_1
  doi: 10.1586/epr.09.80
– ident: e_1_2_8_19_1
  doi: 10.1021/pr070440q
– volume: 27
  start-page: 99
  year: 2006
  ident: e_1_2_8_13_1
  publication-title: Clin. Biochem. Rev./Aus. Assoc. Clin. Biochemists
– ident: e_1_2_8_7_1
  doi: 10.1164/ajrccm.155.3.9117016
– ident: e_1_2_8_18_1
  doi: 10.1002/pmic.200401180
– ident: e_1_2_8_39_1
  doi: 10.1111/j.1365-2796.2003.01211.x
– ident: e_1_2_8_5_1
  doi: 10.1164/ajrccm.152.5.7582312
– ident: e_1_2_8_47_1
  doi: 10.1371/journal.pone.0096285
– volume: 20
  start-page: 698
  year: 2016
  ident: e_1_2_8_12_1
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– ident: e_1_2_8_3_1
  doi: 10.1056/NEJM200007273430407
– ident: e_1_2_8_11_1
  doi: 10.1016/S0140-6736(06)68516-4
– ident: e_1_2_8_54_1
  doi: 10.1164/rccm.201010-1623OC
– ident: e_1_2_8_44_1
  doi: 10.1385/CBB:43:1:167
– ident: e_1_2_8_52_1
  doi: 10.1371/journal.pone.0129291
– ident: e_1_2_8_37_1
  doi: 10.1016/j.thromres.2011.05.004
– ident: e_1_2_8_15_1
  doi: 10.1586/epr.10.9
– ident: e_1_2_8_8_1
  doi: 10.1378/chest.117.2_suppl.10S
– ident: e_1_2_8_20_1
  doi: 10.1164/rccm.200703-409OC
– ident: e_1_2_8_25_1
  doi: 10.1093/nar/gku1003
– ident: e_1_2_8_46_1
  doi: 10.1111/eci.12582
– volume: 144
  start-page: 2371
  year: 1990
  ident: e_1_2_8_50_1
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.144.6.2371
SSID ssj0054270
Score 2.2295136
Snippet Purpose Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to...
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to inhaled...
PurposeChronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and abnormal inflammatory response of the lungs to...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e1700088
SubjectTerms 2D‐page
Aged
Aged, 80 and over
Air flow
Apolipoprotein A
Apolipoproteins
Biomarkers
Blood coagulation
Blood plasma
Blood Proteins - metabolism
Ceruloplasmin
Chronic obstructive pulmonary disease
COPD
Disease control
Female
Gases
Haptoglobin
Humans
Immunoglobulins
Inflammation
Inflammatory response
Lipid metabolism
Lung diseases
Lungs
Male
Metabolism
Middle Aged
Obstructive lung disease
Oxidative stress
Patients
Protein Interaction Mapping
Protein turnover
Proteins
Proteomics
Prothrombin
Pulmonary Disease, Chronic Obstructive - blood
Pulmonary Disease, Chronic Obstructive - metabolism
Two dimensional analysis
Vitamin D
Western blotting
Title Plasma Proteomic Signatures in Early Chronic Obstructive Pulmonary Disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fprca.201700088
https://www.ncbi.nlm.nih.gov/pubmed/29412517
https://www.proquest.com/docview/2033714826
https://www.proquest.com/docview/1999192216
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3PS8MwFMeDePLir_ljOiWC6KnaJmmbHsd0DEEtU8FbSdJUxK0bdhP0r_el6apTRMRrm7Zp33t536TJJwgdCpFC0s3AeWUkHaaUcgSVruMKSG5gZulSs1D48iro3bGLe__-0yp-y4eoB9xMZJTttQlwIYvTD2jo-FkZbpDhy0GkQCNsJmwZVdSv-VE-I-VucR7IdodTFsyojS45nb98Pit9k5rzyrVMPd0VJGaVtjNOnk6mE3mi3r7wHP_zVqtoudKluG0daQ0t6HwdNdo59MmHr_gIlzNFyyH4BrqIQXIPBY4N48GsasY3jw-WEFrgxxyX0GRcYXfxtawYtS8ax9MBuD3UDp_ZH0Mb6K57ftvpOdWeDI6iAWdOxCMZ8TALM8j7YH1oFKQXGjwS6IRMKZ9kmghJtR8oXwhOUw3NKacgy1KdcY9uosV8lOtthFOeUsVSuKv0WUqY0NrVmcdCQtMgC90mcmY2SVQFLDf7ZgwSi1omiflYSf2xmui4Lj-2qI4fS7ZmJk6qkC3gLDX0QuhuNdFBfRqCzfxBEbkeTYvEMBtAEhMPymxZ16gfRSJmxGII1S4N_EsdkrjfaYN6Zjt_LL-LluAgt5MuW2gRTKj3QBhN5H7p_O_XrgVj
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3fT9swEMdPUB62l8EGY-XH5knT9hRIbCdxHit-qGPAKgbS3iLbcRACQkUp0vbXcxcnmTqEponnXFs3d-f7xrE_B_BJ6wKLbonBazITSGttoIUJg1BjcUM3m1DQQeGj42R4Jg9-xu1uQjoL4_kQ3YIbZUY9X1OC04L09h9q6PjWEjiIAHOYKvOwQG29qYnB7klHkIolr_vFRSjcAyVk0nIbQ749-_nZuvRIbM5q17r47C-CaYft95xcbk3vzJb9_RfR8Vn_awleNdKUDXwsvYY5V72B5UGFj-XXv9hnVm8WrVfhl-FghKr7WrMRYR7oYDP7cXHuIaETdlGxmpvMGvIu-24aTO29Y6PpFUY-Do_t-ndDK3C2v3e6MwyatgyBFYmSQaYyk6m0TEss_RgAOC-YKCVCEkqF0tqYl45rI1yc2FhrJQqHM6oSqMwKV6pIvIVedVO5d8AKVQgrC_xWE8uCS-1c6MpIplwUSZmGfQhap-S2YZZT64yr3NOWeU43K-9uVh--dPZjT-t40nKj9XHeZO0ErwoCGOITVx8-dpcx3-gliq7czXSSE7YBVTGP0GbVx0b3UzyTpBdTHHbt4X-MIR-d7AxQQMu1_7T_AC-Gp0eH-eHX42_r8BINlN-DuQE9dKfbRJ10Z97XmfAAKakJfQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3LT9wwEIdHhUoVF_rgtS0UI1XlFEhsJ3GOK2AFtNCIgsQt8hMhIKxYtlL713ccZwPbqkKopxzsJE7G4_n59Rngk5QGg67DyqsKFXGtdSSZiqNYYnBDM6uY-Y3CR8fZ_hk_PE_PH-3iD3yIbsDNe0bTXnsHHxq3_QANHd5pzw3yfDn0lBl4yTO8ell00gGkUk6b4-IS1O2RYDybYBtjuj19_3RY-ktrTkvXJvYMXoOclDosObnaGt-rLf3rD6Dj_3zWG5hvhSnph5r0Fl7Y-h0s9GvslN_8JJ9Js1S0GYNfgMMSNfeNJKWHPPhtzeT75UVAhI7IZU0aajJpubvkm2ohtT8sKcfXWO-xdGQ3zAwtwtlg73RnP2oPZYg0ywSPClGoQuQudxj40fzYKqgk93wkFApO65Q6S6ViNs10KqVgxmJ7KhjqMmOdSNgSzNa3tV0BYoRhmht8qkq5oVxaG1uX8Jwyk7k87kE0sUmlW2K5PzjjugqsZVr5n1V1P6sHm13-YWB1_DPn6sTEVeuzI0xlHl-I_a0ebHTJ6G1-CkXW9nY8qjy0ATUxTTDPcqga3atowb1azLHYjYGfKENVnuz0UT7z98_Mvw6vyt1B9fXg-MsHmMN0ERZgrsIsWtOuoUi6Vx8bP_gNHNsINQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+Proteomic+Signatures+in+Early+Chronic+Obstructive+Pulmonary+Disease&rft.jtitle=Proteomics.+Clinical+applications&rft.au=Baralla%2C+Angela&rft.au=Fois%2C+Alessandro+G&rft.au=Sotgiu%2C+Elisabetta&rft.au=Zinellu%2C+Elisabetta&rft.date=2018-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1862-8346&rft.eissn=1862-8354&rft.volume=12&rft.issue=3&rft_id=info:doi/10.1002%2Fprca.201700088&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1862-8346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1862-8346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1862-8346&client=summon